Thromb Haemost 2000; 83(04): 633-634
DOI: 10.1055/s-0037-1613878
Letters to the Editor
Schattauer GmbH

Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor

R.E. Grossmann
1   From the Central Laboratory of the University Medical Centre, University of Wuerzburg, Wuerzburg, Germany
,
U. Geisen
1   From the Central Laboratory of the University Medical Centre, University of Wuerzburg, Wuerzburg, Germany
,
S. Schwender
1   From the Central Laboratory of the University Medical Centre, University of Wuerzburg, Wuerzburg, Germany
,
F. Keller
1   From the Central Laboratory of the University Medical Centre, University of Wuerzburg, Wuerzburg, Germany
› Author Affiliations
Further Information

Publication History

Received 10 August 1999

Accepted 12 October 1999

Publication Date:
08 December 2017 (online)

 

 
  • References

  • 1 Weiss HJ, Ball AP, Mannucci PM. Incidence of severe von Willebrand’s disease. N Engl J Med 1982; 302: 127.
  • 2 Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N, Lavergne JM. Precipitating antibodies in von Willebrand’s disease. Nature 1976; 262: 141-2.
  • 3 Bergamaschini L, Ciavarella N, Federici A, Di Rocco N, Schiavoni M, Stefanile C, Mannucci PM. Post-transfusional non IgE mediated anaphylaxis in two patients with von Willebrand disease type III with inhibitor: the role of IgG subclasses. Thromb Haemost. 1995 73. (Abstract 1023): 1167.
  • 4 Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of Recombinant Factor VIIa (NovoSeven®) in the Treatment of Two Patients with Type III von Willebrand’s Disease and an Inhibitor against von Willebrand Factor. Haemostasis 1996; 26 (Suppl. 01) 150-4.
  • 5 Majumdar G, Phillips JK, Lavallee H, Savidge GF. Acquired haemophilia in association with Type III von Willebrand’s disease: successful treatment with high purity von Willebrand’s factor and recombinant factor VIIa. Blood Coagulation and Fibrin 1993; 04: 1035-7.
  • 6 Schiavoni M, Valenzano E, Mangini F, Inchingolo F, Micelli M, Mascolo E, Ciavarella N, Erhardtsen E, Hedner U. Efficacy of recombinant factor VIIa (Novoseven) in patients affected by von Willebrand disease type III with alloantibodies against von Willebrand factor in oral surgery. Thromb Haemost. 1997 Suppl. (Abstract 341): 84.
  • 7 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of highdose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99 (03) 542-7.